This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	β -Amyloid ($A\beta$); acetylcholinesterase (AChE); butyrylcholinesterase (BChE)	<i>In vitro</i> studies suggest that glutamic acid-based complexes containing antioxidant and anticholinesterase activities could help treat AD. <i>In vitro</i> , nine compounds that inhibited both AChE and BChE also inhibited $A\beta$ aggregation. The compounds had neuroprotective effects in a human neuroblastoma cell line exposed to oxidative stress and showed good permeability in an artificial blood brain barrier (BBB) model. Next steps could include testing the compounds in animal models of AD. Compounds in Phase III testing for AD include $A\beta$ -targeting mAbs bapineuzumab from Elan Corp. plc and Pfizer Inc. and LY2062430 from Eli Lilly and Co.	Patented by the Spanish National Research Council; licensing status unavailable	Arce, M. <i>et al.</i> <i>J. Med. Chem.</i> ; published online Oct. 26, 2009; doi:10.1021/jm900628z Contact: Santiago Conde, Spanish National Research Council, Madrid, Spain e-mail: sconde@iqm.csic.es
<i>SciBX</i> 2(43); doi:10.1038/scibx.2009.1608 Published online Nov. 5, 2009				